INDEX

Chronic Obstructive Lung Disease is abbreviated as COLD throughout this index.

ACROLEIN
- alpha-antitrypsin effect, 436
- alveolar macrophage effects, 432
- cilioinhibitory effect, 295
- gas phase component, 294, 417

ADDITION
- cessation of smoking, relationship, 468, 481, 485

ADDITIVES
(See also MENTHOL, PHENOL)
- low yield cigarettes, increasing use, 13, 352, 354

ADOLESCENTS
(See also CHILDREN)
- increased cough in smokers, 6
- prevalence of cough and amount smoked, 64
- sex differences in prevalence of respiratory symptoms, 66
- small airways dysfunction in smokers, 37, 427
- smoking rates with smoking and nonsmoking parents, 506

ADVERTISING
(See also MASS MEDIA)
- government regulation of tobacco advertising, 506-507, 514, 520, 527
- promotion of cardiovascular risk reduction, 508
- smoking cessation or reduction effects, 457

AGE DIFFERENCES
- airflow obstruction incidence, 103
- cessation rates in post-MI patients, 475
- cessation success, 468
- chronic airflow obstruction, prevalence, 78
- chronic bronchitis, prevalence, 46-47
- COLD mortality, 191-192, 197, 203-205

AGE DIFFERENCES—Contd.
- cough and phlegm, prevalence, 48, 65-68
- emphysema, severity in smokers and nonsmokers, 126, 241-242
- initiation of smoking and COLD mortality, 209
- lung pathology in smokers, 124-125, 231
- mucociliary transport, 283
- pulmonary function, 6
- pulmonary function in children of smoking parents, 398
- pulmonary function, rate of decline, 9, 137
- reductions in smoking with community intervention studies, 511-512
- small airways dysfunction, 9, 29-30, 32-35, 37-39, 136-137

AIR POLLUTION
(See also PASSIVE SMOKING)
- airflow obstruction relationship, 106
- bronchitis morbidity factor, 212
- COLD mortality factor, 192
- lung clearance effect, 424
- particulates exposure compared with smoking, 417
- workplace levels and pulmonary function, 31

ALCOHOL CONSUMPTION
- abstinence in pregnancy, 462
- airflow obstruction relationship, 106-106

ALLERGY
- atopy and pulmonary function, 100
- lung hypersensitivity and airflow obstruction, 104-105, 118
- skin test reactivity and incidence of airflow obstruction, 103
INDEX

**Alpha,-antiprotease** See **ALPHA,-ANTITRYPSIN**

**ALPHA,-ANTITRYPSIN**
- antiprotease activity, 262–264
- deficiency in panacinar emphysema, 234–235
- elastase inhibition, 8, 11, 301
- oxidants and decreased inhibitory capacity, 273–274, 435
- papain elastolysis, inhibitor, 265
- tobacco smoke effects, 434–437

**Alpha,-proteinase inhibitor** See **ALPHA,-ANTITRYPSIN**

**ALVEOLAR MACROPHAGES**
- changes in smokers, 265–257, 259, 291, 273–279
- changes induced by tobacco smoke, 431–434
- emphysema pathogenesis, role, 268–270
- increased numbers in smokers, 11, 276–279
- increased numbers with nitrogen dioxide, 276
- lung clearance mechanisms, role, 423–424
- neutrophil chemotaxis, role, 258
- toxicity of cigarette smoke, 279–280

**ALVEOLITIS**
- smoking relationship, 255

**AMISH**
- COLD mortality, 213

**AMMONIA**
- gas phase component, 294, 417

**ANGINA**
- contraindication for nicotine chewing gum, 477

**Antibodies** See **IMMUNE SYSTEM**

**ANTISMOKING CAMPAIGNS**
- See also **SMOKING INTERVENTION STUDIES**
- smoking behavior, effect, 457
- smoking cessation at prenatal clinics, effect, 462–463

**ASBESTOS**
- cessation success in exposed shipyard workers, 482–483

**ASTHMA**
- bronchoconstrictive effect of smoke inhalation in asthmatics, 428–429
- children of smoking parents, 389, 403
- mortality in California physicians, 211
- nonsmokers exposed to tobacco smoke, 403, 405–406
- reversibility of airflow obstruction, 75

**ATROPINE**
- cilioinhibitory effect, 295

**AVersive SMOKING**
- cessation effectiveness, 469

**BACTERIA**
- clearance from respiratory tract, 281
- macrophage bactericidal capacity in smokers and nonsmokers, 278–279
- reduced resistance to infection in smoke-exposed animals, 280

**BEHAVIOR MODIFICATION**
- physicians' efforts to get patients to quit, 455
- social reinforcement in community intervention trials, 506

**BIRTHWEIGHT**
- maternal smoking relationship, 461, 464–465

**BRONCHIOLITIS**
- childhood, association with subsequent panacinar emphysema, 236
- (COLD), role in pathogenesis, 11
- pathology, 223, 230–231
- smoking relationship, 242, 255–256

**BRONCHITIS** (See also **MUCUS HYPERSECRETION**)
- abnormalities in regional gas exchange, 22
- aerosol clearance effects, 292–293
- childhood, association with panacinar emphysema, 236
- children of smoking parents, 13, 393, 405
- definition, 45–46, 224
- excessive morbidity in Britain, 212
- mortality and age of smoking initiation, 209–210

536
BRONCHITIS—Contd.
mortality and depth of inhalation, 206
mortality and smoking habit, 201
mortality in physicians, 211
mucociliary dysfunction, 12, 283,
297-302
natural history, 115
particulate phase components, role,
426
pathology, 227, 229
prevalence, 46
smoking relationship, 48, 255
BRONCHOCONSTRICTION
dogs exposed to cigarette smoke,
429
induction by cigarette smoke, 428,
430
inhalation pattern relationship,
349-350
low yield cigarettes effect, 341
CADMIUM
induction of emphysematous lesions
in animals, 276
tobacco smoke component, 426
CARBON DIOXIDE
gas phase component, 417
CARBON MONOXIDE
breath test to demonstrate smoking
effects in pregnant women, 454
breath test to validate self-reported
cessation, 460, 463
gas phase component, 417
increased alveolar epithelial perme-
ability, role, 430
indoor air pollutant, 366, 383
low-tar and low-nicotine cigarettes,
yields, 345-346
CARBOXYHEMOGLOBIN
asthmatics exposed to tobacco
smoke, levels, 403
inhalation pattern relationship,
345, 349
measure of carbon monoxide ab-
sorption, 366, 383
nonsmokers exposed to tobacco
smoke, levels, 384
CARCINOGENESIS
consequence of mucociliary dysfunc-
tion, 301
CASEIN
chemotaxis of polymorphonuclear
leukocytes, effect, 433.

CATALASE
reduction of smoke effects on alpha-
protease inhibitor, 436

CERULOPLASMIN
prevention of alpha-protease ox-
idation, 274

CESSATION OF SMOKING
(See also REDUCTION OF
SMOKING)
cardiopulmonary function improve-
ment, 465
COLD incidence and progression ef-
fects, 7-8
COLD mortality relationship, 10,
210-211, 214
community intervention studies, 15,
503-528
cough and phlegm reduction, 9, 48,
137
emphysema morbidity and mortalit-
y, 126
emphysema severity in ex-smokers,
241-242
emphysematous changes, effect.
127-129
lung clearance effects, 430
mechanical properties of lungs, ef-
fect, 123
morbidity and mortality reduction,
465
mucociliary transport effects, 293,
300
parents, effect on children’s asth-
ma, 403
physicians, 456
pulmonary function effects, 9, 227,
232, 242
pulmonary function effects, rate of
decline, 9, 116-118, 137
reasons given by ex-smokers, 457
respiratory symptoms in ex-smok-
ers, 67
role of physicians, 14, 455-488
sex differences in pulmonary func-
tion effects, 104
small airways function effects, 11,
40-42, 44, 137
CHEST INFECTIONS
airflow obstruction, role in etiology,
83, 107

CHILDREN
(See also ADOLESCENTS)
influence on parental smoking ces-
sation, 468

INDEX
INDEX

CHILDREN—Contd.
pulmonary function effects of smoking, 398 respiratory illnesses and subsequent airflow obstruction, 104, 106, 116 respiratory infections and COLD susceptibility, 7 respiratory symptoms, parental smoking relationship, 13, 388-389, 392-393, 397-398, 402-403, 405 school-based prevention programs, 519-524

CHLORAMINE-T inhibitory capacity of alpha,-antitrypsin, effect, 273-274, 436

CIGAR SMOKERS COLD mortality, 10, 211-212, 214 cough and phlegm prevalence, 48 emphysema incidence at autopsy, 240 former cigarette smokers, 460

Cilia See MUCOCILIARY TRANSPORT

CORONARY HEART DISEASE contraindication for nicotine chewing gum, 477

COTININE nicotine exposure in nonsmokers, measure, 13, 383, 405 urinary levels in children of smoking mothers, 397

COUGH (See also MUCUS HYPERSECRETION) children of smoking parents, 388 contribution to pulmonary clearance, 300 increase in smokers, 6 low yield cigarettes effect, 336-339, 354 prevalence in smokers vs. nonsmokers, 9 tobacco smoke exposure as factor, 386

CREATININE urinary levels in children of smoking mothers, 397

CROSS-CULTURAL STUDIES COLD mortality, 10-11, 212-214

CYSTIC FIBROSIS impairment of mucociliary transport, 283 submucosal gland enlargement, 225

DIABETES contraindication for nicotine chewing gum, 477

EDUCATIONAL ATTAINMENT cessation of smoking, relationship, 462, 468

ELASTASE experimental induction of emphysema, 8, 122-123, 134, 266-270 increase in people deficient in alpha,-antitrypsin, 262 increased activity in smokers, 271, 301 inhibition by alpha,-antitrypsin, 301 inhibition by protease inhibitors, 434-435, 437 low yield cigarettes effects, 340 pathogenesis of COLD, role, 11 physiochemical conditions that modify kinetics, 272-273 proximity in elastin degradation, role, 272 release by macrophages and neutrophils, 267-268, 271-272, 301, 432-434

ELASTIN chemoattractant for blood monocytes, 208 degradation by elastase, 8 degradation by elastase, role of proximity, 272 degradation by papain, 265 synthesis and repair, cigarette smoke effect, 14, 438-439

EMPHYSEMA age of smoking initiation and mortality, 209-210 amount smoked and severity, 11, 137 animal models, 275-278, 433 bronchiolitis as precursor, 256 COLD disease process, 21 definition and characterization, 119-120 detection, 120 gas phase components, role, 426 irreversibility, 75

538
INDEX

EMPHYSEMA—Contd.
  lung clearance mechanisms effect, 424
  mechanical properties of lungs in etiology, 122–123
  mortality in physicians, 211
  oxidants in pathogenesis, 425–427
  pathogenic mechanisms, 11–12, 261, 275–301, 431, 435, 437
  pathology, 223, 226, 230–242
  peripheral airway resistance, 22
  protease-antiprotease imbalances in pathogenesis, 11, 262, 270–278, 301, 339–340
  pulmonary function, 26, 121–122
  quantification, 120–121
  smoking relationship, 8, 10, 125–135, 255
ESOPHAGITIS
  contraindication for nicotine chewing gum, 477
EXERCISE
  cessation in post-MI patients, effect, 475
  lung deposition of aerosols, effect, 421
  promotion in community intervention studies, 508
EYES
  irritation following acute exposure to tobacco smoke, 13, 386–387, 406
FAMILY
  influence of support on smoking cessation, 457, 485, 506
  recidivism prevention in post-MI patients, 475
FIBROBLASTS
  membrane damage caused by tobacco smoke, 438
FIBROSIS
  lung clearance mechanisms, effect, 424
FILTER CIGARETTES—Contd.
  pulmonary function effects, 116
GENETIC FACTORS
  development of airflow obstruction, 104, 106–107
GROUP COUNSELING
  cessation rates in post-MI patients, effect, 475
HEADACHE
  after acute exposure to tobacco smoke, 386
HEXAMETHONIUM
  cilioinhibitory effect, 295
HISTAMINE
  involvement in bronchoconstrictive response to smoking, 428
  reactivity in smokers and nonsmokers, 430
  release in animals exposed to tobacco smoke, 429
HYDROGEN CYANIDE
  ciliotoxicity, 283, 289
HYDROGEN PEROXIDE
  alpha,-protease inhibition, effect, 436
  enhanced production in alveolar macrophages in smokers, 432
  inactivation of alpha,-antitrypsin, 274
HYPERKINESIS
  maternal smoking relationship, 461
HYPERTENSION
  cardiovascular risk reduction program, factor, 515
  contraindication for nicotine chewing gum, 477
  pulmonary artery, association with chronic airflow obstruction, 232
HYPERTHYROIDISM
  contraindication for nicotine chewing gum, 477
IMMUNE SYSTEM
  ABH antigens and airflow obstruction, 105
  COLD susceptibility, factor, 7
  smoking effects, 12, 255, 279–281, 301
INDEX

INFLUENZA
increased susceptibility in smokers, 12, 200, 301

Involuntary smoking See PASSIVE SMOKING

ISOPRENE
mucociliary transport effects, 295

ISOPROTERENOL
reversal of airways reactivity, 105

LACTATION
inhibition by maternal smoking, 461

LEAD
particulate phase component, 417

LEGISLATION
restrictions on smoking in public places, 507, 514, 520, 527

LOBELINE
nicotine substitute, 458

LOW YIELD CIGARETTES
(See also FILTER CIGARETTES)
additives, 13, 352-354
cessation success and tar yield, 461
COLD mortality, 198, 201, 203
COLD risk, 12-13, 336-341, 354
lung cancer mortality relationship, 339
mucociliary transport effects, 294
particulate concentrations and size, 418-419
research recommendations, 353
respiratory symptoms, 66
smoking behavior effects, 341-348, 354
tar yield and respiratory symptoms, 60

LUNG CANCER
aerosol deposition at bronchogenic carcinoma sites, 422
low yield cigarettes relationship, 339
mortality in smokers, 336
polonium deposition and site of bronchogenic carcinoma, 424
smoking behavior relationship, 333
smoking relationship, 255

LUNGS

cigarette-induced disease, pathology, 11
growth in children of smoking mothers, 398
localization of emphysematous lesions, 275

LUNGS—Contd.
pulmonary epithelial permeability and smoking, 430-431, 439
tissue repair, cigarette smoking effects, 437

Macrophages See ALVEOLAR MACROPHAGES

MARITAL STATUS
cessation of smoking, relationship, 468-469

MASS MEDIA
(See also ADVERTISING)
antismoking educational campaigns, 480
community intervention studies, 15, 506, 506, 514, 523, 526, 528
televised smoking cessation classes, 519

MATERNAL SMOKING
(See also PARENTAL SMOKING; PREGNANCY)
fetal and childhood effects, 461
prenatal smoking and respiratory infections in children, 393

METHACHOLINE
responsiveness and airways reactivity, 105
responsiveness and smoking, 428-429

METHOL
mucociliary transport effects, 295

Minority groups See RACIAL/ETHNIC DIFFERENCES

MORBIDITY
bronchitis in Britain, 212
chronic airflow obstruction, 68-118
chronic mucus hypersecretion, 45-73
COLD prevalence and inhalation practices, 209
emphysema, 119-135
improvement following cessation of smoking, 465
small airways dysfunction, 22-44
smoking and COLD morbidity, 8-10

MORTALITY
cardiovascular diseases, declines related to risk factor reduction program, 515
cessation of smoking relationship, 465
COLD, airflow obstruction relationship, 339
INDEX

MORTALITY—Contd.
COLD, mucus hypersecretion relationship, 339
COLD, smoking relationship, 8, 10–11, 169–214, 336
fetal and neonatal, maternal smoking effect, 461
myocardial infarction patients who quit smoking, 470
predictive effectiveness of FEV₁, 72

MUCOCILIARY TRANSPORT
chronic bronchitis, 297–301
filters, effect, 296–297
lung clearance of deposited particulates, 423–424
normal function, 283–286
smoke constituents, effect, 293–296, 426
tobacco smoke, effect, 12, 290–296, 301–302, 418, 431

MUCUS HYPERSECRETION
cigarette smoke effects, 11, 107, 292, 302
COLD disease process, 21
COLD mortality relationship, 339
cough and phlegm, relationship to airflow obstruction, 68–73
cough and phlegm, relationship to sex and age, 65–68
cough and phlegm, relationship to smoking, 47–48, 63–65
inhalation depth relationship, 349
low yield cigarettes, effect, 350–359, 354
measurement of cough and phlegm, 45–46
phlegm in smokers vs. nonsmokers, 9
prevalence and amount smoked, 137
prevalence of cough and phlegm, 46–47

MYELOPEROXIDASE
inactivation of alpha,-antitrypsin, 274, 436–437

MYOCARDIAL INFARCTION
cessation of smoking in post-MI patients, 15, 470, 475–476, 480–481, 487
contraindication for nicotine chewing gum, 477

N-CHLORSUCCINIMIDE
reduction of activity of alpha,-antitrypsin, 436

NEUTROPHILS
changes induced by tobacco smoke, 255–261, 432–434
chemotaxis inhibition by cigarette smoke, 269–270
decrease following elastase instillation, 266
increased numbers in smokers, 11, 256–257, 270–271, 301
increased numbers with nitrogen dioxide, 276
migration in response to macrophage chemotactic factor, 258

NICOTINE
alpha,-protease inhibitor effect, 436
alveolar epithelial permeability effect, 430
blood levels with nicotine chewing gum, 476
bronchial reactivity effect in baboons, 430
bronchoconstriction effect, 428
chemokinetic factor for neutrophils, 258, 432–433
compensatory behavior in smokers of low nicotine cigarettes, 421
DNA synthesis effect, 280
indoor air pollutant, 366
machine-determined yields and actual intake, 335–336, 346–347
mucociliary transport effects, 295
nonsmokers exposed to tobacco smoke, levels, 303
particulate phase component, 417
reinforcer of smoking behavior, 13
saliva levels to validate cessation reports, 459

NICOTINE CHEWING GUM
cessation aid, 14, 460, 476–478, 487

NITRIC OXIDE
mucociliary transport effects, 295

NITROGEN DIOXIDE
effect on macrophages, 279
emphysematous lesions in animals, role in induction, 276
gas phase component, 294
mucociliary transport effects, 295
INDEX

NITROGEN OXIDES
- acute bronchoospasm effects, 428
- epithelial permeability effects, 430-431
- gas phase component, 417
- indoor air pollutant, 366
- lung clearance mechanisms, toxic effects, 424

NITROSAMINES
- indoor air pollutants, 366

Nonsmokers See PASSIVE SMOKING

NOSE
- irritation following acute exposure to tobacco smoke, 386

NURSES
- involvement in community intervention studies, 514

OCCUPATIONS
(See also WORKPLACE)
- coal miners, 230, 234, 240
- grain elevator workers, 31
- industrial workers, 277
- iron foundry workers, 42
- physicians, 14-15, 194, 198, 206, 298, 299, 219-211, 455-456, 511, 514, 527
- shipyard workers, 482-483
- steelworkers, 30, 43
- textile workers, 225, 242

OZONE
- lung clearance mechanisms, toxic effects, 424
- preexposure and cigarette smoke effects in animals, 437

PAPAIN
- emphysema pathogenesis, role, 266-266

PARENTHAL SMOKING
(See also MATERNAL SMOKING)
- children's encouragement to quit, effect, 519-520
- influence on adolescent smoking rates, 506
- pulmonary function in children, 397-398, 405
- respiratory infections in children, 393, 397, 405
- respiratory symptoms in children, 13, 385-389, 392, 403, 405

PARTICULATES
(See also TARS, TOBACCO)

PARTICULATES—Contd.
- aerodynamic diameter, 418-420, 438
- exposure measurement, 383
- indoor air pollutants, 366
- ingestion by pulmonary macrophages, 259
- lung deposition, 420-422, 425, 438
- lung retention, 423-424

PASSIVE SMOKING
- acute airway response, 384, 386
- children, respiratory infections related to parental smoking, 393, 397
- children, subsequent susceptibility to COLD, 7
- COLD risk effect, 13
- deposition of particulates in lungs, 425
- exposure measurement, 316, 383-384
- patients with preexisting pulmonary disease, 403-405
- prevalence of respiratory symptoms, 66
- pulmonary function in children, parental smoking relationship, 397-402
- pulmonary function relationship, 402-403
- sidestream vs. mainstream smoke, 365-366
- symptomatic responses, 386-392

PEPSIN
- emphysema induction in experimental animals, 123

PEPTIC ULCER
- contraindication for nicotine chewing gum, 477

PERIODISATE
- transfer across tracheal epithelium, 431

PERSONALITY
- cessation of smoking factor, 469, 481-482, 485

PHENOL
- mucociliary transport effects, 295-296

PHENYLCHLOROXADIAZOLOL
- anticiliotoxic effects, 296

PHENYLCHLOROXADIAZOLOL
- anticiliotoxic effects, 296
INDEX

PHLEGM See MUCUS HYPERSECRETION

PHYSICIANS
- cessation of smoking and COLD mortality, 210–211
- COLD mortality, 194, 198, 206, 208
- involvement in community intervention studies, 511, 514, 527
- smoking cessation in patients, role, 14–15, 455–488
- smoking prevalence, 14, 456

PIPE SMOKERS
- COLD mortality, 10, 211–212, 214
- cough and phlegm prevalence, 48
- emphysema incidence at autopsy, 240
- former cigarette smokers, 460

PNEUMOCONIOSIS
- pathology, 225, 234

PNEUMONIA
- children of smoking parents, 13, 393, 406

POLONIUM
- deposition at site of bronchogenic carcinoma, 424
- particulate phase component, 417

POLYCYCLIC AROMATIC HYDROCARBONS
- fibroblast membrane effects, 438

Polymorphonuclear leukocytes See NEUTROPHILS

PREGNANCY
(See also MATERNAL SMOKING)
- antibody production in pregnant smokers, 280
- cessation of smoking, 14, 479–480, 487
- motivation for quitting, 484
- physician intervention and cessation of smoking, 461–465

PREVENTION OF SMOKING
- community intervention studies, 15, 520–524

PROTEASE-ANTIPROTEASE IMBALANCE
- alpha-antitrypsin deficiency, 130
- effect of oxidants, 275
- emphysema pathogenesis, 11, 262, 270–278, 301, 339–340
- smoke exposure effect, 277–278

PULMONARY FUNCTION
- airway lesions relationship, 227, 229
- asthma patients, 13, 403, 405–406

PULMONARY FUNCTION—Contd.
- children of smoking parents, 13, 393, 397–398, 405
- cigarette smoke effects, 6, 9, 191, 497–430, 438
- emphysema, 121–122
- expiratory airflow obstruction as COLD disease process, 21
- inflammation and small airways dysfunction, 11
- inhalation depth relationship, 349
- low yield cigarettes relationship, 337–338, 354
- occupational exposure relationship, 107
- passive smoking effects, 13, 384–386, 402–403, 405
- people deficient in alpha-antitrypsin, 262
- small airways dysfunction, 22–44, 136–137, 227

RACIAL/ETHNIC DIFFERENCES
- cessation of smoking during pregnancy, 462
- chronic airflow obstruction, prevalence, 78
- COLD mortality, 11, 191, 214
- COLD risk, 212-213
- serum concentrations of alpha-antitrypsin, 263
- smoking prevalence trends, 504

REDUCTION OF SMOKING
(See also CESSATION OF SMOKING)
- physician intervention, effectiveness, 458–459
- pregnant women, 463–465
- psychologist’s advice, effectiveness, 466–469

RESPIRATORY SYNCYTIAL VIRUS INFECTION
- children of smoking mothers, 393, 397

SEX DIFFERENCES
- airflow obstruction prevalence, 78, 83
INDEX

SEX DIFFERENCES—Contd.
cessation of smoking, 468
cessation rates in post-MI patients, 475
cholesterol reduction, 512
chronic bronchitis mortality, 210
chronic bronchitis prevalence, 46-47
COLD mortality, 10, 189, 192, 203-207, 213-214
community intervention effectiveness, 511, 514
cough and phlegm prevalence, 48, 65-68
emphysema incidence at autopsy, 240-241
emphysema severity at autopsy, 241-242
particulates deposition, 423
preventive effect of school-based smoking interventions, 522
pulmonary function after passive smoking, 384-386
reduction of smoking following physician intervention, 488-489
small airways dysfunction, 9, 28, 37-40, 137
smoking patterns and pulmonary function, 32-33, 35, 104
smoking prevalence, 504
Small airways disease See PULMONARY FUNCTION
SMOKING BEHAVIOR
cigarette yields, effect, 13, 64, 334-335
inhalation pattern and cessation probability, 469
inhalation pattern and COLD mortality, 208-209, 214
inhalation pattern and COLD susceptibility, 7, 348-352, 354
low yield cigarettes relationship, 12-13, 341-348, 354
lung deposition of particulates, effect, 420-423, 425
lung injury relationship, 341
SMOKING INTERVENTION STUDIES
(See also ANTIMOKING CAMPAIGNS)
cessation and prevention effects, 15
community cessation studies, 504-505, 507-520, 528
SMOKING INTERVENTION STUDIES
community prevention studies, 520-524, 528
methodological issues, 524-526, 528
research needs, 526-528
theoretical basis, 505-507
SMOKING-MACHINES
comparability to actual smoking behavior, 12, 64, 333-336, 341, 354, 421-421
SMOKING PATTERNS
age of initiation and COLD mortality, 209-210
alveolar macrophage changes and amount smoked, 256
cessation probability and amount smoked, 459, 469, 481
COLD morbidity relationship, 9
COLD mortality and amount smoked, 10, 198, 201, 203, 205-208, 210-211, 213-214
COLD severity relationship, 336
cough and phlegm prevalence, 9, 47-48, 137
determinants of airflow obstruction, 92, 103-104
emphysema at autopsy and amount smoked, 240-241
emphysema severity, 10, 137
emphysematous changes and amount smoked, 126-127
mucus hypersecretion and amount smoked, 63-65
pulmonary function and amount smoked, 6-7, 9, 69, 115, 117, 131, 137
respiratory symptoms prevalence, 73
small airways dysfunction and amount smoked, 32-35, 38, 43, 136-137
SMOKING PREVALENCE
physicians, 456, 487
trends in various demographic groups, 503-504
SOCIOECONOMIC STATUS
cessation of smoking, relationship, 468-469
pulmonary function relationship, 108
reduction in tobacco consumption in higher income groups, 509
smoking prevalence, 525-526, 528
trend toward reduced smoking, 15

544
INDEX

**Sputum** See MUCUS HYPERSECRETION

**STRESS**
- cessation success relationship, 481-482
- chronic smoking relationship, 357
- management training to maintain nonsmoking, 509

**SUPEROXIDE DISMUTASE**
- activity depression by tobacco smoke, 434
- reduction of smoke effects on alpha-protease inhibitor, 496

**SUPEROXIDE RADICALS**
- alpha-protease inhibitor activity, effect, 436
- generation by alveolar macrophages in smokers, 259, 432
- release from neutrophils in smokers, 433

**TARS, TOBACCO** (See also PARTICULATES)
- ciliotoxic effect, 295
- cough and phlegm production relationship, 337
- exposure in nonsmokers, 384
- mucus hypersecretion relationship, 12, 339
- pulmonary function relationship, 338
- respiratory symptoms effect, 65
- smoking behavior relationship, 13, 347-348, 354

**TAXES**
- increases as part of community intervention trials, 514

**TAXES—Contd.**
- revenues contributed by tobacco industry, 503
- smoking deterrent effectiveness, 457, 507, 520, 527

**THIOCYANATE**
- plasma levels to validate self-reports of cessation, 512
- saliva levels to validate self-reports of cessation, 464
- serum levels to validate self-reports of cessation, 508-509, 511, 513, 518, 521-522

**TOBACCO SMOKE**
- aerosol characterization, 417-420, 438
- deposition and toxicity, 14
- mainstream vs. sidestream smoke, 366-366
- toxicology, 426-439

**TRACHEA**
- epithelial permeability in smoke-exposed animals, 430-431

**WHEEZING**
- children of smoking parents, 388-389, 392-393

**WOOD SMOKE**
- airflow obstruction, etiologic factor, 83

**WORKPLACE** (See also OCCUPATIONS)
- air pollution and pulmonary function, 31
- smoking prohibitions and cessation, 457